- Home
- NEOV vs GNLX Comparison
NEOV vs GNLX Comparison
Compare NEOV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- GNLX
- Stock Information
- Founded
- NEOV 2018
- GNLX 2001
- Country
- NEOV United States
- GNLX United States
- Employees
- NEOV N/A
- GNLX N/A
- Industry
- NEOV Industrial Machinery/Components
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- GNLX Health Care
- Exchange
- NEOV Nasdaq
- GNLX Nasdaq
- Market Cap
- NEOV 131.0M
- GNLX 128.0M
- IPO Year
- NEOV N/A
- GNLX 2023
- Fundamental
- Price
- NEOV $3.88
- GNLX $3.56
- Analyst Decision
- NEOV Strong Buy
- GNLX Strong Buy
- Analyst Count
- NEOV 1
- GNLX 4
- Target Price
- NEOV $7.50
- GNLX $17.75
- AVG Volume (30 Days)
- NEOV 173.4K
- GNLX 106.8K
- Earning Date
- NEOV 11-07-2025
- GNLX 08-07-2025
- Dividend Yield
- NEOV N/A
- GNLX N/A
- EPS Growth
- NEOV N/A
- GNLX N/A
- EPS
- NEOV N/A
- GNLX N/A
- Revenue
- NEOV $4,255,136.00
- GNLX N/A
- Revenue This Year
- NEOV $208.50
- GNLX N/A
- Revenue Next Year
- NEOV $128.75
- GNLX N/A
- P/E Ratio
- NEOV N/A
- GNLX N/A
- Revenue Growth
- NEOV 52.64
- GNLX N/A
- 52 Week Low
- NEOV $1.80
- GNLX $1.95
- 52 Week High
- NEOV $6.11
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- NEOV 48.70
- GNLX 53.77
- Support Level
- NEOV $3.40
- GNLX $3.26
- Resistance Level
- NEOV $3.86
- GNLX $3.61
- Average True Range (ATR)
- NEOV 0.32
- GNLX 0.23
- MACD
- NEOV 0.01
- GNLX -0.02
- Stochastic Oscillator
- NEOV 63.21
- GNLX 37.04
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.